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Abstract 
The long-term objective of this project is to utilize the I-domain protein for the -subunit of 
LFA-1 to target drugs to lymphocytes by binding to ICAM receptors on the cell surface. The 
short-term goal is to provide proof-of-concept that I-domain conjugated to small molecules 
can still bind to and uptake by ICAM-1 on the surface of lymphocytes (i.e., Raji cells). To 
accomplish this goal, the I-domain protein was labeled with FITC at several lysine residues to 
produce the FITC-I-domain and CD spectroscopy showed that the FITC-I-domain has a 
secondary structure similar to that of the parent I-domain. The FITC-I-domain was taken up 
by Raji cells via receptor-mediated endocytosis and its uptake can be blocked by anti-I-domain 
mAb but not by its isotype control. Antibodies to ICAM-1 enhance the binding of I-domain to 
ICAM-1, suggesting it binds to ICAM-1 at different sites than the antibodies. The results in-
dicate that fluorophore modification does not alter the binding and uptake properties of the 
I-domain  protein.  Thus,  I-domain  could  be  useful  as  a  carrier  of  drug  to  target 
ICAM-1-expressing lymphocytes. 
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INTRODUCTION 
Intercellular adhesion molecule-1 (ICAM-1) is an 
Ig-like  transmembrane  glycoprotein  constitutively 
expressed on several cell types, including leukocytes 
and dendritic cells. ICAM-1 is an attractive target for 
drug delivery to immune cells, since its expression is 
elevated  in  several  autoimmune  disorders  [1-7].  In-
creased  ICAM-1  expression  has  been  observed  on 
T-cells isolated from synovial fluid and brain tissue of 
patients suffering from rheumatoid arthritis and mul-
tiple  sclerosis,  respectively  [1-3,  8-9].  Elevated 
ICAM-1 expression is thought to be a direct conse-
quence of inflammatory cytokines released upon the 
infiltration  of  T-cells  at  the  site  of  destruction.  The 
infiltration of T-cells progressively modifies the clini-
cal outcome of the autoimmune diseases by enhanc-
ing the immunogenic response. Cell adhesion mole-
cules (CAM), including ICAM-1, are internalized into 
the  cell  cytoplasmic  domain  via  a  unique  pathway Theranostics 2011, 1 
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referred  to  as  CAM-mediated  endocytosis  [10-13]. 
Ligands that bind to CAM can be used to selectively 
target drugs for intracellular delivery to immune cells 
expressing  these  upregulated  adhesion  molecules. 
Therefore, I-domain can be utilized to target drugs to 
cells with upregulated ICAM-1 during inflammation. 
ICAM-1 targeting offers not only surface binding but 
also intracellular drug delivery. 
The natural counter-receptor of ICAM-1 is leu-
kocyte  function  associated  antigen-1  (LFA-1,  αLβ2, 
CD11a/CD18),  a  transmembrane  cell  surface  glyco-
protein [14-15]. It belongs to the integrin superfamily 
of adhesion molecules, widely expressed on immune 
cell  subsets.  It  is  comprised  of  heterodimeric  α 
(180kDa)  and  β  (95kDa)  subunits,  which  are 
non-covalently  associated  [16-17].  The  α-subunit 
(CD11a)  of  LFA-1  consists  of  an  amino  termi-
nal-inserted-domain  (I-domain,  approximately  200 
amino acids), which is necessary for LFA-1 binding to 
ICAM-1. The I-domain is structurally located at the 
top of the α-subunit with a central five-stranded par-
allel β-sheet surrounded by seven α-helices; it has two 
important sites for modulation of binding to ICAM-1 
[17-18]. The first site is a unique metal ion-dependent 
adhesion  site  (MIDAS).  The  I-domain  binds  to  do-
main-1  (D1)  of  ICAM-1  through  its  MIDAS,  which 
involves coordination of a divalent cation (i.e., Mg2+ 
or Ca2+) via the Asp137, Ser139, Ser141, Thr206 and 
Asp239 residues [19-20]. The second important site is 
the  I-domain  allosteric  site  (IDAS)  [21].  IDAS  is  an 
important binding site for small molecule inhibitors of 
ICAM-1/LFA-1-mediated  cell-cell  adhesion  [22]. 
Although the I-domain protein has long been studied, 
I-domain protein alone not conjugated to nanoparti-
cles for potential use as a carrier for drug targeting has 
not  been  investigated  to  date.  Therefore,  we  have 
begun to investigate the utility of the I-domain to de-
liver drugs and antigenic peptides to immune cells for 
controlling  autoimmune  diseases  such  as  multiple 
sclerosis, rheumatoid arthritis, and type-1 diabetes. 
In this work, we studied the binding and uptake 
properties  of  the  fluorescence-labeled  I-domain 
(FITC-I-domain) by ICAM-1 on Raji cells. In the fu-
ture, I-domain will be conjugated to drug molecules 
to  direct  the  drugs  to  cells  with  overexpressing 
ICAM-1 for lowering the drug side effects [10-13]. As 
a model conjugate, several of the lysine residues of the 
I-domain  were  derivatized  with  fluorescein  isothio-
cyanate (FITC) to generate FITC-I-domain. The bind-
ing properties of FITC-I-domain to ICAM-1 on Raji 
cells after incubation at 4 °C and 37 °C were charac-
terized by flow cytometry as well as binding modula-
tion using anti-I-domain antibody. The cellular local-
ization of FITC-I-domain was determined by confocal 
microscope, and the amounts of the I-domain on the 
cell  surface  and  in  the  intracellular  compartments 
were  determined  using  fluorescence  intensity  inte-
grations.  Finally,  the  effect  of  divalent  cations  on 
binding  FITC-I-domain  to  ICAM-1  was  also  deter-
mined. 
MATERIALS AND METHODS  
Materials: 
Fluorescein  isothiocyanate  (FITC)  isomer-I, 
phorbol 12-myristate-13-acetate (PMA), tumor necro-
sis factor- (TNF-) and human IgG were purchased 
from  Sigma-Aldrich  (St.  Louis,  MO). 
4',6-Diamidino-2-phenylindole  (DAPI)  and  Alexa 
Fluor
 647 phalloidin were purchased from Molecular 
Probes  (Eugene,  OR).  Anti-human-ICAM-1  mAb  to 
domain  D1  (clone  15.2),  mouse  IgG1  (clone 
MOPC31C),  anti-human  LFA-1  CD11a  (clone  38), 
mouse IgG2a (clone RPC 5), and polyclonal goat an-
ti-mouse IgG/IgM FITC were purchased from Ancell 
Cooperation (Bayport, MN).  
Cell culture: 
Cells  were  purchased  from  ATCC  (Rockville, 
MD) and propagated in an RPMI-1640 medium con-
taining  10%  v/v  fetal  bovine  serum,  100  units/mL 
penicillin G sodium, 100 μg/mL streptomycin sulfate, 
and 2.0 g/l NaHCO3. The cells were maintained at a 
density of 1.5 × 106 to 2 × 106/mL at 37 °C in 95% 
humidified  and  5%  CO2 atmosphere.  As  necessary, 
MOLT-3 cells were activated in medium containing 
PMA for 16 h or TNF- for 24 h with final concentra-
tions of 0.2 μM and 10 ng/mL, respectively. 
Protein expression and purification: 
The expression of I-domain has been described 
elsewhere [23]. Briefly, the I-domain DNA sequence 
was  subcloned  into  pET-11d  vector  followed  by 
transformation  into  competent  E.  coli  BL21  cells 
(Stratagene, La Jolla, CA). Then, the E. coli cells were 
cultured and the induction of protein overexpression 
was done using isopropyl D-thio-galactoside (IPTG, 
Sigma-Aldrich). For isolating the protein, the cell pel-
lets  were  lysed  in  10  mL  of  homogenization  buffer 
(HB) using a French press followed by centrifugation 
(20000  ×  g)  at  4  °C  for  1  h.  The  majority  of  the 
I-domain  was  found  in  the  protein  pellet.  After 
washing, the cell pellet was resuspended in 15 mL of 
denaturing  buffer  (DB,  6  M  guanidine-HCl  and  50 
mM Tris, pH 8.5) and incubated for 1 h at room tem-
perature before centrifugation for 30 min to remove 
the  remaining  cell  debris.  The  supernatant  was  di-
luted  to  a  protein  concentration  of  1  mg/mL  and 
concentrated with Amicon
 ultrafiltration cell (Milli-Theranostics 2011, 1 
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pore) with 5,000 MWCO ultra-filtration membranes. 
After dialysis against RFB and PBS containing 10 mM 
MgSO4 at 4 °C, the folded I-domain protein was puri-
fied  by  passing  it  through  a  Superdex  200 
size-exclusion  column  (Amersham  Biosciences, 
Pittsburgh, PA) [24]. The protein was concentrated to 
10 mg/mL, and the concentration was measured at 
280  nm  using  an  extinction  coefficient  of  8940  M-1 
cm-1. The purity of the I-domain was determined by 
SDS-PAGE gel and confirmed by electrospray ioniza-
tion mass spectrometry (ESI-MS) with an m/z ratio of 
1881.2  corresponding  to  [M  +  11H].  The  secondary 
structure of the folded protein was determined using 
far-UV circular dichroism (CD). 
Conjugation of FITC to the I-domain to give FITC-I-domain: 
The conjugation of FITC to the I-domain protein 
was performed by following the method previously 
described  [25].  Briefly,  one-fourth  volume  of  1.0  M 
NaHCO3/Na2CO3  buffer  pH  9.0  was  added  to  the 
I-domain solution (6 mg/mL) followed by addition of 
a 25-fold molar excess of freshly prepared FITC solu-
tion (5 mg/mL) in DMSO. The mixture was stirred in 
the dark for 2 h at 25 °C. At the end of the reaction, the 
pH was readjusted to 7.4 using 0.1 N HCl. Immedi-
ately the mixture was purified to separate the conju-
gated protein from free FITC using a Superdex 200 
size-exclusion  column.  The  fractions  for  the 
FITC-I-domain  were  collected  and  concentrated  by 
ultrafiltration.  The  concentration  of  the  pure  conju-
gated  protein  was  determined  using  a  UV  method 
described previously [25] by measuring the absorb-
ance at 280 nm and 495 nm following the equation: 
Concentration of I-domain protein (mg/mL) = 
[A280-(0.35 × A495)]/0.432 
where 0.432 is the A280 of I-domain at a concentration 
of 1.0 mg/mL and 0.35 × A495 is the correction factor 
due to the absorbance of FITC at 280 nm. The purity of 
the  FITC-I-domain  conjugate  was  confirmed  by 
SDS-PAGE  gel,  and  the  number  of  FITC  molecules 
conjugated to the I-domain protein was determined 
by ESI-MS. The effect of conjugation on the secondary 
structure was evaluated by comparing the CD spec-
trum of the I-domain conjugate and that of the parent 
I-domain. 
Flow cytometry: 
Cell preparation:  The  cell  preparation  described 
here was carried out in the same manner for all the 
experiments  described  below.  Cells  from  the  stock 
were centrifuged at 500 × g for 5 min and then resus-
pended in sterile PBS to reach a concentration of 5 × 
105/mL.  Aliquots  of  1.0  mL  of  the  cell  suspension 
were added to 1.5 mL centrifuge tubes followed by 
centrifugation at 500 × g. The resulting supernatants 
were carefully aspirated without disturbing the cell 
pellets;  the  pellets  were  used  for  the  following  ex-
periments.  
Determination of cell surface expression of ICAM-1 
receptor: To decrease the non-specific binding, 20 µL of 
human IgG (300 µg/mL) in FACS buffer containing 
PBS  (10  mM  sodium  phosphate,  150  mM  sodium 
chloride pH 7.2-7.5, 1% BSA, and 0.05% sodium azide) 
was added to the cell pellets and incubated for 5 min 
at 4 °C. Then, 80 µL of anti-CD54 (clone 15.2) or iso-
type control primary antibody sub-stock ranging from 
20  to  0.0006  µg/mL  dilutions  in  FACS  buffer  was 
added to the cells, followed by incubation for 45 min 
at  4  °C.  The  cells  were  washed  twice  with  0.5  mL 
FACS buffer and centrifuged at 500 × g for 5 min. Into 
the cell pellet, 50 µL of FITC-labeled secondary anti-
body (1:60 dilution) was added and incubated for 30 
min  at  4  °C,  followed  by  extensive  washing  with 
FACS buffer. The cell pellet was resuspended in 300 
µL  2%  paraformaldehyde/PBS  and  stored  at  4  °C 
prior to analysis. The samples were analyzed using a 
FACScan  apparatus  (Becton  Dickinson,  Franklin 
Lakes,  NJ)  equipped  with  CELL  QUEST  software 
program. As many as 10,000 cells were counted for 
every sample during acquisition, and each experiment 
was done at least in triplicate. Cells without antibody 
treatment  were  used  as  controls.  The  control  histo-
gram was placed within 100 to 101 on the log scale of 
fluorescence  intensity  by  adjusting  the  fluorescence 
detector. The binding intensities were represented as 
their relative values to the reference conditions and 
were determined from the mean values of the histo-
grams for cell number and log fluorescence intensity 
(mean  fluorescence  intensity  (MFI)  corrected  for 
non-specific fluorescence). 
Concentration-  and  temperature-dependent  binding 
of the FITC-I-domain protein: The cell pellet was resus-
pended in PBS containing increasing concentrations 
of FITC-I-domain protein from 0 to 52 µM at 4 °C and 
up to 156 µM at 37 °C and incubated for 60 min. At the 
end of the incubation period, the cells were washed 
three times with FACS buffer, and the cell suspension 
was centrifuged at 500 × g for 5 min. The cells were 
fixed using 2% paraformaldehyde/PBS. The resulting 
samples were analyzed using flow cytometry, and the 
MFI was determined as described above. 
The  effect  of  anti-LFA-1  mAb  on  FITC-I-domain 
binding:  Binding  of  FITC-I-domain  to  ICAM-1  was 
also  evaluated  in  the  presence  of  anti-LFA-1  (an-
ti-CD11a)  mAb.  For  blocking  studies,  5  µM 
FITC-I-domain  was  first  incubated  with  equimolar 
amounts of anti-LFA-1 (clone 38) mAb or its isotype 
control antibody in buffer for 30 min at 37 °C; then, Theranostics 2011, 1 
 
http://www.thno.org 
280 
this mixture was added to cells pretreated with hu-
man IgG and incubated for 1 h at 37 °C. The cell sus-
pension  was  centrifuged,  washed,  and  fixed  before 
analysis by flow cytometry. 
 Divalent  cation-dependent  binding  of  the 
FITC-I-domain protein: The cells were incubated for 1 h 
at 37 °C with FITC-I-domain protein (25 µM) in the 
absence and presence of 1.5 mM CaCl2, MgCl2, MnCl2, 
CaCl2/EDTA, MgCl2/EDTA, or MnCl2/EDTA in PBS. 
After  incubation,  the  cells  were  treated  as  shown 
above prior to flow cytometry analysis. 
Time-  and  temperature-dependent  binding  of  the 
FITC-I-domain protein: The cells were incubated with 
100  µL  of  25  µM  FITC-I-domain  prepared  in  FACS 
buffer for 0, 5, 10, 15, 30, 60, 120, 180, and 360 min at 4 
°C and 37 °C. After washing and fixing, the cells were 
subjected to flow cytometry analysis. 
Confocal microscopy study: 
Raji cells were centrifuged (500 × g) for 5 min 
and re-suspended in sterile warm PBS to a final con-
centration of 2.5 × 105/mL, and 1.0 mL aliquots were 
dispensed into nine centrifuge tubes. After centrifu-
gation (500 × g) and removal of the supernatant solu-
tion, 10 µL of FACS buffer was added to cells pellets, 
and the cell suspension was equilibrated for 5 min at 
either 4 °C or 37 °C. Then, 15 µL of FITC-I-domain 
(100 µM) was added to the cell suspension and incu-
bated for 0, 5, 10, 15, 30, 60, 120, 180, and 360 min. At 
each time point, cells were centrifuged, washed twice 
(with FACS buffer), and fixed with 100 µL of 4% par-
aformaldehyde in PBS. To the fixed cells, 100 µL of 
16.5 nM Alexa Fluor® 647 phalloidin for actin staining 
and 12.5 µL of 5 µM DAPI for nuclear staining were 
added followed by overnight incubation at 4 °C. The 
following day, these samples were mounted on a slide 
and imaged using a Yokugawa CSU-10 spinning disk 
confocal unit attached to an Olympus IX-81 inverted 
microscope platform (Olympus America, Inc., Center 
Valley, PA) Images were captured using a Hamama-
tsu C9100 electron multiplier 1000 × 1000 pixel CCD 
camera and the SlideBook software package (Intelli-
gent Imaging Innovations, Denver, CO). The resulting 
images were analyzed using the program CellProfiler 
to segment regions of interest for measuring fluores-
cence intensity associated with the membrane and the 
cytoplasm for each cell examined [26].  
Statistical analysis: 
All the values obtained in the above experiments 
were  expressed  as  mean  ±  SE.  The  differences  be-
tween groups were tested for statistical significance 
using Student's t-test. The presence of significant dif-
ference is denoted with p-values of < 0.05, < 0.01 or 
<0.001. 
RESULTS 
Fluorescein conjugation to I-domain: 
The I-domain has been successfully conjugated 
with fluorescein group at several of the 20 lysine res-
idues to make FITC-I-domain (Figure S1/Scheme 1). 
Reproducibility of the conjugation was achieved by 
optimizing the pH, ratio of I-domain/FITC, temper-
ature, and reaction time. The FITC-I-domain was eas-
ily  separated  from  the  excess  FITC  using  SEC  (Fig. 
1A).  The  pure  FITC-I-domain  shows  only  a  single 
band  on  SDS-PAGE  when  stained  with  Coomassie 
blue or upon shining UV light on the gel (lane 4, Fig. 
1B). In contrast, the crude reaction product shows two 
spots by Coomassie blue and three fluorescent spots 
by UV light (lane 2, Fig. 1B) and the parent I-domain 
only shows one spot by Coomassie blue and no spot 
found by UV (lane 3, Fig. 1B).  
 
 
 
Figure S1. Scheme 1. Reaction of I-domain protein with 
FITC along with the reaction conditions listed. 
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The  ESI-MS  data  indicate  one  to  seven  FITC 
groups attached to the I-domain with an average of 
3.5  FITC  groups  per  I-domain  molecule  (top  panel, 
Fig. 1C). There is no unconjugated I-domain with a 
MW  of  20,682  found  in  the  MS  spectrum  (bottom 
panel, Fig. 1C). The CD spectrum of FITC-I-domain is 
same as the spectrum of unmodified I-domain (Fig. 
1D) indicating that there is no conformational change 
in  the  FITC-I-domain.  The  predicted  secondary 
structure  of  FITC-I-domain  from  CD  spectra  shows 
37% α-helix and 26% β-sheet, which very similar to 
the  secondary  structure  content  derived  from  the 
crystal structure (i.e., 37% α-helix and 22% β-sheet) 
[27]. 
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Figure 1. A. Separation of the FITC-conjugated I-domain protein from the unreacted (free) FITC using size-exclusion 
chromatography (SEC). B. SDS-PAGE analysis of pure FITC-I-domain protein after staining with Coomassie blue (left) and 
before staining under UV light (right): molecular weight marker (lane 1), reaction mixture of I-domain protein and FITC (lane 
2),  unmodified  I-domain  protein  (lane  3),  and  FITC-conjugated  I-domain  protein  (lane  4).  C.  ESI-MS  analysis  of  the 
FITC-I-domain protein (top) and the I-domain protein (bottom). D. CD spectra of unmodified I-domain protein (solid 
circles), and FITC conjugated I-domain protein (open squares).  
 
Figure 2. Comparison of the surface expression of ICAM-1 receptors in different cell lines using anti-ICAM-1 (CD54) mAb 
15.2. Data shown from one representative experiment ± S.E. (n = 3) for Raji cells and (n = 1) for Molt-3 and HL-60. 
 
Comparison of ICAM-1 expression on Raji, HL-60, and 
Molt-3 cells: 
The  ICAM-1  expressions  on  HL-60,  Molt-3 
T-cells  and  Raji  cells  were  determined  using  an-
ti-ICAM-1 D1 (clone 15.2) mAb to select the appro-
priate cells for FITC-I-domain binding studies (Fig. 2). 
In all of three cell lines, the anti-ICAM-1 mAb binding 
increased  upon  increase  in  antibody  concentration, 
saturation  at  high  concentrations.  The  highest 
ICAM-1  level  was  found  in  Raji  cells  followed  by 
Molt-3 cells and HL-60 cells. As a negative control, the 
isotype mAb did not show any appreciable binding to 
all three cells. Upon induction with TNF-α or PMA, 
the expression of ICAM-1 was slightly increased in Theranostics 2011, 1 
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Molt-3; however, the increase in ICAM-1 expression 
did  not  match  the  amount  of  ICAM-1  on  the 
un-activated Raji cells. Based on these results, the Raji 
cells were used to perform binding experiments using 
FITC-I-domain protein.  
FITC-I-domain binding to ICAM-1 on Raji Cells:  
At 4 °C, the FITC-I-domain exhibited an increase 
in binding with saturation up to 30 µM of added pro-
tein  when  it  leveled  off  (Fig.  3A).  At  37  °C, 
FITC-I-domain binding had two stages (Fig. 3B). The 
first stage has a tight binding with a steep binding 
slope for 0–8 µM and plateau between 8 and 10 µM. 
The second stage a weaker binding of I-domain with a 
shallow binding slope between 10 and 156 µM; this 
binding does not show saturation at a high concen-
tration  (156  µM),  indicating  the  process  of  binding 
and receptor-mediated uptake of FITC-I-domain at 37 
°C unlike at 4 °C. Confocal microscopy was used to 
study the uptake properties of the conjugate. 
 
Figure 3. Binding of FITC-I-domain to ICAM-1-expressing 
Raji cells at 4 °C (A) and 37 °C (B). The results are ex-
pressed as the mean ± S.E. (n = 3). 
The effect of anti-LFA-1 mAb on FITC-I-domain binding:  
The effect of anti-LFA-1 (anti-CD11a, clone 38) 
and anti-ICAM-1 mAb on binding of FITC-I-domain 
to  ICAM-1  was  determined  to  access  its  ICAM-1 
specificity.  Anti-CD11a  mAb  binds  to  I-domain  of 
LFA-1. It blocked 55% of FITC-I-domain binding to 
Raji cells; in contrast, the isotype control mAb did not 
block  the  FITC-I-domain  binding  (Fig.  4).  These  re-
sults  are  consistent  with  previously  reported  data 
using cell based assay [28] and solid phase ELISA [29]. 
 
 
 
Figure 4. Effect of anti-LFA-1 (CD11a) I-domain mAb on 
the binding of FITC-I-domain protein to the ICAM-1 re-
ceptor expressed on the surface of Raji cells. The results 
are expressed as the mean ± S.E. (n = 3). There are signif-
icant differences in the binding of FITC-I-domain protein; 
control vs. mAb 38 (*p<0.01). 
 
Ca2+ enhances binding of FITC-I-domain to ICAM-1:  
The  active  state  of  I-domain  interacts  with 
Glu-34  of  ICAM-1  via  its  MIDAS  region  through  a 
coordination of a divalent metal ion. Thus, the effect 
of  various  divalent  cations  on  binding  affinity  of 
FITC-I-domain to ICAM-1 on Raji cells was evaluated. 
Ca2+ significantly enhances binding of FITC-I-domain 
to the cells compared to Mg2+ or Mn2+ and no divalent 
cations (Fig. 5). The increase in FITC-I-domain bind-
ing  could  be  reversed  to  normal  using  Ca2+  and 
EDTA,  suggesting  the  involvement  of  Ca2+  in  the 
MIDAS  region  of  FITC-I-domain  during  binding  to 
ICAM-1. Finally, the presence of EDTA in Mg2+- or 
Mn2+-containing  media  shows  binding  of 
FITC-I-domain similar to that of control (absence of 
cations).  These  results  indicate  that  Ca2+  is  a  better 
coordination  cation  than  Mg2+  or  Mn2+  for 
FITC-I-domain binding to ICAM-1. 
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Figure  5.  Effect  of  divalent  cations  on  FITC-I-domain 
binding to ICAM-1 receptors expressed on the surface of 
Raji cells. The results are expressed as the mean ± S.E. (n = 
3). There are significant differences in the binding of the 
FITC-I-domain protein; control vs. CaCl2 (*p<0.05). 
 
FITC-I-domain uptake by Raji cells:  
The results of concentration-dependent binding 
studies suggest that FITC-I-domain binds to the cell 
surface  only  at  4  °C;  however,  a  combination  of 
binding and uptake of FITC-I-domain is observed at 
37  °C  (Fig.  3).  To  determine  the  uptake  properties, 
time- dependent binding at 4 °C and 37 °C was stud-
ied by flow cytometry (Fig. 6). At 37 °C, 64% of bind-
ing  was  observed  within  5  min;  100%  binding  was 
arbitrarily  assigned  to  fluorescence  intensity  at  the 
360-min  time  point  with  a  plateau  starting  at  the 
30-min  point.  A  three-fold  decrease  in  the  fluores-
cence intensity was found upon 4 °C incubation of the 
protein, suggesting that the difference in fluorescence 
intensities at 37 and 4 °C was due to protein uptake. 
To visualize the binding and uptake, Raji cells 
were incubated with FITC-I-domain at either 4 °C or 
37 °C with increasing incubation time up to 360 min. 
This was followed by capturing a confocal Z-section 
series over a depth of 12-microns. The green fluores-
cence from the protein could be clearly identified in 
the cells treated at 37 °C (Fig. 7A) as early as the 5-min 
time  point.  In  contrast,  only  limited  green  fluores-
cence was found associated with the cells incubated 
with the protein at 4 °C (Fig. 7B).  
 
 
Figure 6. FITC-I-domain protein binding to Raji cells at 37 °C (closed bars) and 4 °C (open bars) as a function of time. The 
values for the mean fluorescence intensity were obtained using flow cytometry. The results are expressed as the mean ± S.E. 
(n = 3). There are significant differences in the binding of FITC-I-domain protein at 5, 10, 15, 30, 60, 90, 120, 180, and 360 
min; 4 °C vs. 37 °C (p<0.001). Theranostics 2011, 1 
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Figure 7. A. Confocal microscopy images of FITC-I-domain binding to ICAM-1 on the surface of Raji cells at 37 °C with 
increasing incubation time (0, 5, 10, 15, 30, 60, 120, 180, and 360 min). Raji cells stained with DAPI (blue) for the nucleus, 
Alexa Fluor® 647 Phalloidin (red) for actin, and FITC-I-domain (green). Phase contrast image (first row), DAPI (second 
row), FITC-I-domain (third row), Alexa Fluor® 647 Phalloidin (fourth row), and merged image of all the three colors (fifth 
row). B. Confocal microscopy images of FITC-I-domain binding to ICAM-1 on the surface of Raji cells at 4 °C with increasing 
incubation time (0, 5, 10, 15, 30, 60, 120, 180, and 360 min). Raji cells stained with DAPI (blue) for the nucleus, Alexa Fluor® 
647  Phalloidin  (red)  for  actin,  and  FITC-I-domain  (green).  Phase  contrast  image  (first  row),  DAPI  (second  row), 
FITC-I-domain (third row), Alexa Fluor® 647 Phalloidin (fourth row), and merged image of all the three colors (fifth row). 
 
To differentiate surface binding and intracellular 
uptake of FITC-I-domain, the cell nucleus and actin 
were stained with DAPI and Alexa Fluor® 647 phal-
loidin, respectively. Using the CellProfiler cell image 
analysis software, captured images were segmented 
and  processed  for  green  fluorescence  from 
FITC-I-domain  associated  with  regions  defined  as 
either the whole cell (i.e., region of DAPI staining plus 
the region of Phalloidin-Alexa Fluor® 647 staining) or 
the cytoplasm (i.e., regions of Phalloidin-Alexa Fluor® 
647  staining)  alone.  The  average  integrated  fluores-
cence intensity (AIF) values associated with the whole 
cell upon protein incubation at 37 °C were increased 
upon longer incubation time compared to those in-
cubated at 4 °C (data not shown); these results were 
consistent with data from flow cytometry. Similarly, 
the  AIF  values  associated  with  the  cyctoplasm  or 
membranes were higher at 37 °C than at 4 °C (data not 
shown). The AIF intensity values associated with the 
cytoplasm was slightly lower compared to AIF inten-
sity in the membranes (Fig. 8). These results indicate 
that FITC-I-domain conjugate binds and internalizes 
in B-cells at 37 °C.  Theranostics 2011, 1 
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Figure 8. FITC-I-domain protein binding to Raji cells at 37 °C. The values for the average integrated fluorescence intensities 
associated with cytoplasm (open bars) and membrane (closed bars) were obtained from the analysis of the confocal images 
using cell image analysis software, CellProfiler. 
 
DISCUSSION 
This study is the first to show that I-domain can 
enter the intracellular space of Raji cells via a recep-
tor-mediated endocytosis process. Previously, cLABL 
peptide derived from the sequence of I-domain was 
found in the intracellular space of T-cells upon bind-
ing  and  ICAM-1-mediated  endocytosis  [30].  Nano-
particles  decorated  with  cLABL  peptide  or  an-
ti-ICAM-1 antibody were also endocytosed into cel-
lular compartments (i.e., endosomes) upon binding to 
ICAM-1  on  the  cell  surface  [13,  31-32].  Recently, 
I-domain mutants with high affinity to ICAM-1 have 
been used to target nanoparticles encapsulated with 
drugs and diagnostic agents to tumor cells with up-
regulated ICAM-1 [33]. However, I-domain alone and 
its mutants without conjugation to nanoparticles have 
not been investigated to deliver drugs to cells with 
upregulated  ICAM-1.  Anti-ICAM-1-coated  nanopar-
ticles  successfully  delivered  lysosomal  enzyme  into 
cells obtained from patients suffering from lysosomal 
storage disorder [34]. These nanoparticles are endo-
cytosed via a non-classical mechanism upon ICAM-1 
clustering, which is called CAM-mediated endocyto-
sis. The CAM-mediated endocytosis is distinct from 
classical  clathrin-  or  caveolar-mediated  internaliza-
tion as well as from phagocytosis and micropinocyto-
sis processes [13, 35]. 
ICAM-1 has important roles in different patho-
logical  conditions  such  as  autoimmune  diseases, 
[36-37] cancer, [36, 38] and atherosclerosis [39]. The level 
of ICAM-1 expression is increased in several diseases; these 
include  autoimmune  disorders  (e.g.,  rheumatoid  ar-
thritis, type-1 diabetes, and lupus), malignancies (e.g., 
multiple myeloma, lymphomas, lung, and pancreatic can-
cer), inflammatory disorders (e.g., allergic inflammation, 
asthma),  atherosclerosis,  ischemia,  neurological  dis-
orders (e.g., Alzheimer’s disease), and allogeneic or-
gan transplantation [36, 40]. Upregulation of ICAM-1 is 
also found on the endothelium during inflammation, 
which is influenced by cytokines (i.e., TNF-, IL-1 and 
IFN-),  and  this  upregulation  induces  adhesion  of 
leukocytes prior to subsequent trans-endothelial mi-
gration  to  the  injured  tissue  [40-43].  Cell  surface 
ICAM-1 molecules serve as endocytosis receptors for 
human  rhinovirus  (HRV)  and  respiratory  syncytial 
virus [44-45]. Thus, the I-domain can be explored as a 
carrier to target drugs to leukocytes, cancer cells, and 
inflammatory  endothelial  cells  with  up-regulated 
ICAM-1 receptors. The hope is that the I-domain-drug 
conjugate can direct the drug molecule to the target 
pathogenic  cells  while  at  the  same  time  avoiding 
normal cells to minimize the toxic side-effects of the 
drug. The small drugs can be conjugated to several of 
the 20 Lys residues of the I-domain. Here, several of 
these Lys residues of the I-domain were conjugated 
with FITC groups and still maintained the I-domain 
conformation (Fig. 1C), ICAM-1-binding (Fig. 3), and 
uptake  properties  (Figs.  6–8).  We  have  determined 
using tryptic mapping, mass spectrometry, and mo-
lecular modeling that the FITC-conjugated Lys resi-
dues are away from the binding site of I-domain to 
ICAM-1. 
FITC-I-domain binds to ICAM-1 on Raji cells in a Theranostics 2011, 1 
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way  that  can  be  inhibited  by  anti-LFA-1  I-domain 
mAb (clone 38), suggesting that this antibody blocks 
the I-domain binding site to ICAM-1 (Fig. 4). A similar 
effect of the mAb was observed in the binding of a 
GST-tagged  I-domain  (I-GST)  to  a  surface-coated 
ICAM-1Fc using a solid-phase ELISA assay [29]. The 
antibody  blocking  studies  indicate  that 
FITC-I-domain binds to ICAM-1 on Raji cells, and the 
presence of FITC labels does not alter its binding to 
ICAM-1. 
The binding of FITC-I-domain to ICAM-1 is en-
hanced by Ca2+ ion but not Mg2+ or Mn2+ ions (Fig. 5); 
this increase in binding can be reversed upon addition 
of EDTA. It is interesting that only Ca2+ ion enhances 
the binding of FITC-I-domain to ICAM-1; this could 
be due to the fact that Ca2+ has the appropriate size 
and  electrostatic  interaction  compared  to  Mg2+  and 
Mn2+  to  coordinate  with  the  MIDAS  region  of  the 
I-domain and the Glu-34 residue of ICAM-1. Griggs et 
al. have shown that calcium can bind to the isolated 
I-domain and can compete with Mn2+, though calcium 
appears  to  have  a  slightly  lower affinity  [20].  Mn2+ 
strongly augmented the binding of LFA-1 expressed 
on the surface of T-cells to its ligand, ICAM-1, [46] 
suggesting that Mn2+ is able to induce conformational 
changes  in  LFA-1  favoring  the  high  affinity  state. 
Binding of Mg2+ with in the I-domain also results in a 
conformational  change  such  that  the  C-terminal  7 
helix swings away from the central -sheet, resulting 
in a high affinity form of I-domain [47]. 
Receptor-mediated  internalization,  along  with 
other  technological  advances  in  drug  conjugation, 
may be a useful application for I-domain in targeting 
drugs to inflammatory diseases, autoimmune diseas-
es, and cancer. Recently, we have successfully conju-
gated an antigenic peptide with an I-domain protein 
via a linker. The antigenic peptide-I-domain conjugate 
effectively  suppressed  experimental  autoimmune 
encephalomyelitis  (EAE)  in  female  SJL/J  mice  as  a 
model for human multiple sclerosis. 
We  believe  that  FITC-I-domain  binding  to 
ICAM-1 on the cell surface induces ICAM-1 cluster-
ing, further initiating the internalization of the con-
jugate via an ATP-dependent process. We speculate 
that this is CAM-mediated endocytosis. The binding 
sites on ICAM-1 for HRV and LFA-1 are distinct with 
partial overlaps in the binding residues. Studies done 
using ICAM-1 mutants revealed that the binding site 
for HRV on ICAM-1 is Gln 58, while for LFA-1 is Glu 
34 [48]. Antibodies can selectively bind to the target 
receptor, but it is not guaranteed that such interac-
tions necessarily result in endocytosis. In vitro and in 
vivo  animal  studies  done  using  anti-ICAM-1  have 
shown  that  the  ICAM  antibody  internalizes  poorly 
[49].  In  contrast,  targeting  using  LFA-1 
I-domain-conjugates  is  mediated  by  the  compara-
tively natural interaction between the I-domain and 
its ligand ICAM-1 receptor. Therefore, I-domain con-
jugates  may offer an alternate solution for selective 
and effective internalization.  
ICAM-1 targeting offers a variety of applications. 
ICAM-1-targeted isotopes were used for detection of 
lung  inflammation  at  a  very  early  stage  [50].  Lipo-
somes conjugated with anti-ICAM-1 were able to bind 
to  epithelial  and  endothelial  cells  in  a  dose-  and 
time-dependent manner [51]. Murciano et al. demon-
strated  the  delivery  of  an  anti-ICAM-1  conjugated 
tissue-type plasminogen activator (tPA) to endothelial 
cells in vitro and in an in vivo animal model [49] Thus, 
ICAM-1 targeting has been utilized for imaging, di-
agnosis, and delivery of therapeutic agents.  
CONCLUSIONS 
In  this  paper,  we  have  shown  that  the 
FITC-I-domain can bind to ICAM-1 on the surface of 
B-cells.  The  conjugate  binding  is  influenced  by  the 
presence of calcium. Further, the conjugate is inter-
nalized  by  ICAM-1  on  B-cells,  probably  via  recep-
tor-mediated  endocytosis,  suggesting  that  the 
I-domain can be used to target drugs to the cytoplas-
mic compartment of cells expressing ICAM-1. In the 
future, the utility of I-domain proteins in delivering 
anti-inflammatory,  anti-cancer,  and  antigenic  pep-
tides will be investigated.  
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